Eichler, Martin and Andreou, Dimosthenis and Golcher, Henriette and Hentschel, Leopold and Richter, Stephan and Hohenberger, Peter and Kasper, Bernd and Pink, Daniel and Jakob, Jens and Ashmawy, Hany and Hettmer, Simone and Tuchscherer, Armin and Grube, Matthias and Heidt, Vitali and Jentsch, Christina and Pablik, Jessica and Wardelmann, Eva and Kreitner, Karl-Friedrich and Kneser, Ulrich and Tonus, Carolin and Wimberger, Pauline and Schoffer, Olaf and Reichardt, Peter and Wartenberg, Markus and Eberlein-Gonska, Maria and Bornhauser, Martin and Schmitt, Jochen and Schuler, Markus K. (2021) Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study. ONCOLOGY RESEARCH AND TREATMENT, 44 (6). pp. 301-312. ISSN 2296-5270, 2296-5262
Full text not available from this repository. (Request a copy)Abstract
Background: Data on institutional structures of sarcoma care in Germany are scarce. The utilization of an interdisciplinary tumor board (IDTB) is an essential part of modern cancer care. We investigated to which extent and when IDTB are used in sarcoma care. We hypothesized that IDTB before treatment initiation were used more often at certified cancer centers and at high-volume centers and that IDTB utilization increased over time. Methods: From 2017 to 2020 we conducted a prospective cohort study, undertaking major efforts to include the whole spectrum of sarcoma treatment facilities. To analyze potential predictors of IDTB utilization, we calculated multivariable logistic regressions. Results: Patients and survivors (n = 1,309) from 39 study centers (22 tertiary referral hospitals, 9 other hospitals, and 8 office-based practices) participated; 88.3% of the patients were discussed at some stage of their disease in an IDTB (56.1% before treatment, 78% after therapy, and 85.9% in metastatic disease). Hypotheses were confirmed regarding the utilization of IDTB in certified cancer centers (vs. all others: OR = 5.39; 95% CI 3.28-8.85) and the time of diagnosis (2018/2019 vs. until 2013: OR = 4.95; 95% CI 2.67-9.21). Conclusion:Our study adds to the evidence regarding the institutional structures of sarcoma care in Germany. Utilization of a tumor board before therapy seems to be in an implementation process that is making progress but is far from complete. Certification is a possible tool to accelerate this development.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | SOFT-TISSUE; GUIDELINES; Sarcoma care; Sarcoma treatment and diagnosis; Tumor board utilization; Observational study; Orphan disease |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Sep 2022 14:06 |
| Last Modified: | 30 Sep 2022 14:06 |
| URI: | https://pred.uni-regensburg.de/id/eprint/48155 |
Actions (login required)
 |
View Item |
